United States · Series B startup

Who invested in Simcha Therapeutics

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$40Mraised across 1 round since 2022, from 1 source

Latest round
Series B, $40MJan 2022
Investors
4
See who backed them

The rounds

  1. Jan 2022
    Series B$40M

    Source recordedSEC filing: $40M sold, first sale Aug 2021

Everyone who backed them

HSGVC firm1round
Connecticut InnovationsGovernment1round
SR OneCorporate VC1round
Samsara BioCapitalVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Simcha Therapeutics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Kohlmann & CoPrivate equityPer its own site

Quick answers about Simcha Therapeutics

Who invested in Simcha Therapeutics?

Simcha Therapeutics's investors include HSG, Connecticut Innovations, SR One and Samsara BioCapital.

How much has Simcha Therapeutics raised?

Simcha Therapeutics has raised $40M across 1 round since 2022.

When did Simcha Therapeutics last raise?

Simcha Therapeutics's most recent round was a Series B of $40M in Jan 2022.

What was Simcha Therapeutics's biggest round?

Its most recent round, $40M in Jan 2022, is also its largest on record.

Who backed Simcha Therapeutics first?

Simcha Therapeutics's first round on record, in Jan 2022, was backed by HSG, Connecticut Innovations and SR One and 1 others.

What stage is Simcha Therapeutics at?

Simcha Therapeutics's latest named round is a Series B, in Jan 2022.

Where is Simcha Therapeutics based?

Simcha Therapeutics is based in the United States.

Companies like Simcha Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.